Literature DB >> 2036715

Angiotensin degradation products mediate endothelium-dependent dilation of rabbit brain arterioles.

R L Haberl1, P J Decker, K M Einhäupl.   

Abstract

This study demonstrates that the hexapeptide angiotensin II-(3-8) and L-arginine, generated through enzymatic degradation of angiotensin, mediate endothelium-dependent dilation in rabbit brain arterioles. Topical application of angiotensin II (10(-5) M) on the brain surface of anesthetized rabbits caused 21.6 +/- 4.5% (mean +/- SEM) cerebral arteriolar dilation. The cyclooxygenase inhibitor indomethacin did not change this dilation. The natural degradation product of angiotensin II in the brain, angiotensin III, also induced vasodilation at concentrations of 10(-7) to 10(-5) M. The dilation to angiotensin II and angiotensin III was eliminated in the presence of 10(-5) M methylene blue, a known inhibitor of endothelium-dependent vasodilation. Amastatin, an aminopeptidase inhibitor and blocker of enzymatic angiotensin degradation, also inhibited the response to angiotensin II and angiotensin III. The angiotensin fragment angiotensin II-(3-8), which lacks the amino-terminal L-arginine residue of angiotensin III, did not elicit an arteriolar response. When angiotensin II-(3-8) was topically applied subsequent to L-arginine, a 21.2 +/- 2.9% vasodilation was observed. L-Arginine itself induced only moderate vasodilation with a maximum of 4.0 +/- 0.9% at 10(-5) M L-arginine. The dilating response to angiotensin II-(3-8) after L-arginine was inhibited by methylene blue. It was not affected by amastatin. It is concluded that degradation products of angiotensin, rather than angiotensin II itself, induce endothelium-dependent dilation in rabbit brain arterioles without involvement of cyclooxygenase products.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2036715     DOI: 10.1161/01.res.68.6.1621

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  16 in total

Review 1.  Angiotensin and cerebral blood flow.

Authors:  J M Saavedra; Y Nishimura
Journal:  Cell Mol Neurobiol       Date:  1999-10       Impact factor: 5.046

2.  Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning.

Authors:  J W Wright; L Stubley; E S Pederson; E A Kramár; J M Hanesworth; J W Harding
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

3.  Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole.

Authors:  S Arima; Y Endo; H Yaoita; K Omata; S Ogawa; K Tsunoda; M Abe; K Takeuchi; K Abe; S Ito
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

4.  Angiotensin IV Receptors Mediate the Cognitive and Cerebrovascular Benefits of Losartan in a Mouse Model of Alzheimer's Disease.

Authors:  Jessika Royea; Luqing Zhang; Xin-Kang Tong; Edith Hamel
Journal:  J Neurosci       Date:  2017-05-05       Impact factor: 6.167

Review 5.  Brain angiotensin II and angiotensin IV receptors as potential Alzheimer's disease therapeutic targets.

Authors:  Jessika Royea; Edith Hamel
Journal:  Geroscience       Date:  2020-07-22       Impact factor: 7.713

6.  Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.

Authors:  D M Kerins; Q Hao; D E Vaughan
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

7.  Modulation by nitric oxide and prostaglandin of the renal vascular response to angiotensin II (3-8).

Authors:  M Yoshida; M Kikukawa; H Hisa; S Satoh
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

8.  Regional haemodynamic effects of angiotensin II (3-8) in conscious rats.

Authors:  S M Gardiner; P A Kemp; J E March; T Bennett
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

Review 9.  Neurovascular and Cognitive failure in Alzheimer's Disease: Benefits of Cardiovascular Therapy.

Authors:  Edith Hamel; Jessika Royea; Brice Ongali; Xin-Kang Tong
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

10.  The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition.

Authors:  Ihab Hajjar; Meaghan Hart; William Milberg; Vera Novak; Lewis Lipsitz
Journal:  BMC Geriatr       Date:  2009-11-18       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.